Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial

Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era

(2019) James N. Gerson et al.   JOURNAL OF CLINICAL ONCOLOGY

MINIMAL RESIDUAL DISEASE (MRD) IN NON‐HODGKIN LYMPHOMAS: INTER‐LABORATORY REPRODUCIBILITY ON MARROW SAMPLES WITH VERY LOW LEVELS OF DISEASE WITHIN THE FIL (FONDAZIONE ITALIANA LINFOMI) MRD NETWORK

(2019) I. Della Starza et al.   HEMATOLOGICAL ONCOLOGY

Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

(2017) Catherine Thieblemont et al.   JOURNAL OF CLINICAL ONCOLOGY

Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma

(2017) Steven Le Gouill et al.   NEW ENGLAND JOURNAL OF MEDICINE

Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial

(2017) Sarah A Holstein et al.   Lancet Haematology

15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau

(2016) Christian W. Eskelund et al.   BRITISH JOURNAL OF HAEMATOLOGY

Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network

(2016) Eva Hoster et al.   JOURNAL OF CLINICAL ONCOLOGY

Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network

(2016) Olivier Hermine et al.   LANCET

Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial

(2016) Marek Trněný et al.   LANCET ONCOLOGY

Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma

(2015) John G. Gribben et al.   JOURNAL OF CLINICAL ONCOLOGY

Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2014) M. Dreyling et al.   ANNALS OF ONCOLOGY

Treatment of Older Patients with Mantle-Cell Lymphoma

(2012) H.C. Kluin-Nelemans et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era

(2010) P. Perez-Galan et al.   BLOOD

High-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting in mantle cell lymphoma: a 10-year update of the R-HDS regimen

(2008) M Magni et al.   BONE MARROW TRANSPLANTATION

Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma

(2008) Annina Herrmann et al.   JOURNAL OF CLINICAL ONCOLOGY

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

(2007) E. Hoster et al.   BLOOD